NasdaqCM:DNTHBiotechs
Dianthus Therapeutics (DNTH) Is Up 18.7% After Claseprubart Trial Progress Reshapes Its Autoimmune Focus
Dianthus Therapeutics recently attracted fresh attention as investors reacted to progress in its clinical-stage complement therapeutics pipeline, including mid-to-late-stage trials of claseprubart in several autoimmune neuromuscular conditions and an early-stage study of DNTH212 in systemic lupus erythematosus.
An interesting angle for investors is how these parallel programs, alongside lead candidate DNTH103, position Dianthus as a focused player in complement-targeted treatments for severe...